中国造埃博拉药物挽救生命却卷入专利纠纷_时事

中国造埃博拉药物挽救生命却卷入专利纠纷

After a nurse who contracted Ebola in Sierra Leonewas discharged Wednesday from a Rome hospital, adoctor there described the experimental treatmentsthe patient had received as “absolutely miraculous.

在塞拉利昂感染埃博拉病毒的一位护士周三从罗马一家医院出院，该院一位医生形容病患接受的试验治疗的效果“绝对如奇迹一般。

They included MIL77, a product from China that wasalso given to a British Army nurse who recoveredfrom Ebola at a London hospital in March. It is a nearcopy of what many believed was the most promisingEbola therapy: a cocktail of antibodies known as ZMapp, the result of a collaboration betweenthe United States and Canada.

治疗中使用了中国生产的MIL77，伦敦一家医院在三月也用这个药品治疗了一位感染埃博拉的英国陆军护士，现已治愈。该药几乎原样复制了最被人看好的埃博拉疗法，也就是被称作ZMapp的抗体综合剂，后者是美国与加拿大合作的成果。

While ZMapp was mired in production delays last fall and winter and quickly becameunavailable, a small private Chinese company, Beijing Mabworks, raced ahead, helpingproduce about 100 doses of MIL77. That means more potentially lifesaving treatments fordesperate patients. But it has also led to patent infringement concerns by American officials,and to disagreements over when experimental Ebola therapies should be offered to patientsonly in carefully controlled studies and when they should be made more available forcompassionate reasons.